Privacy·Terms·Disclaimer

Bibliographic data courtesy of the U.S. National Library of Medicine (NLM), sourced from PubMed/MEDLINE.

SciRadar is not affiliated with, endorsed by, or sponsored by NLM or NCBI. Abstracts remain © their respective publishers.

Targeting the gate: The rise of Sec61 inhibitors in cancer therapy. — SciRadar

Back to results

The Journal of pharmacology and experimental therapeutics

Targeting the gate: The rise of Sec61 inhibitors in cancer therapy.

Solomon Tadesse, Elizabeth Kaweesa

Published: 202510.1016/j.jpet.2025.103721

No abstract available for this study.